CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.76: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
7.75%
Annual Rate
CNY 2.30Paid unknown
Payout Ratio
0.0%Sustainable
Payback Period
12.5 yr
Last Ex-Dividend
Sep 11, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.56BCNY528.68M · vs all stocks (USD)
Revenue (TTM)
326.02MCNY48.48M · vs all stocks (USD)
Profit Margin
-10.05%vs Biotechnology peers
Beta
0.7500xvs all stocks
52-Week Change
-33.31%vs all stocks
Forward Annual Dividend Yield
7.75%vs all stocks
Market Capitalization
3.56BCNY528.68M · vs all stocks (USD)
Enterprise Value
2.51BCNY373.51M · vs all stocks (USD)
Price to Sales (TTM)
10.90xvs Biotechnology peers
Price to Book (MRQ)
1.21xvs Biotechnology peers
Enterprise to Revenue
7.70xvs Biotechnology peers
Enterprise to EBITDA
-149.17xvs Biotechnology peers
Gross Margin
58.72%vs Biotechnology peers
Profit Margin
-10.05%vs Biotechnology peers
Operating Margin
15.08%vs Biotechnology peers
Return on Assets (TTM)
-1.08%vs Biotechnology peers
Return on Equity (TTM)
-1.05%vs Biotechnology peers
Revenue (TTM)
326.02MCNY48.48M · vs all stocks (USD)
Revenue per Share (TTM)
2.63CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-14.20%vs Biotechnology peers
Gross Profit (TTM)
183.16MCNY27.24M · vs all stocks (USD)
EBITDA (TTM)
8.58MCNY1.28M · vs all stocks (USD)
Net Income (TTM)
-32.78MCNY-4.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
64.80%vs Biotechnology peers
Operating Cash Flow (TTM)
23.43MCNY3.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.99MCNY-890.48K · vs all stocks (USD)
Forward Annual Dividend Rate
2.30CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
7.75%vs all stocks
Trailing Annual Dividend Rate
2.30CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
7.75%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
339.05MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
124.92MCNYFY2025 · Dec 31, 2025Gross Profit
214.13MCNYFY2025 · Dec 31, 2025Operating Income
-58.97MCNY-8.77M · vs all stocks (USD)
Pre-tax Income
-32.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.02MCNYFY2025 · Dec 31, 2025Net Income
-41.08MCNYFY2025 · Dec 31, 2025EBIT
-23.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
8.58MCNYFY2025 · Dec 31, 2025Research & Development
78.72MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
67.53MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.53MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
83.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
83.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.08MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-47.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-110.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
483.51MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
37.61MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-44.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
763.74KCNYFY2025 · Dec 31, 2025Capital Expenditures
-63.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.53BCNYFY2025 · Dec 31, 2025Sale of Investments
4.40BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-193.29MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
648.04MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-510.40MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-293.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
-6.68MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-162.11MCNYFY2025 · Dec 31, 2025Shares Outstanding
124.13MSharesUpdated Aug 21, 2026Float Shares
63.12MSharesUpdated Aug 21, 2026% Held by Insiders
46.42%vs all stocks
% Held by Institutions
0.67%vs all stocks
Total Cash (MRQ)
1.69BCNY251.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.62CNYUpdated Aug 21, 2026Total Debt (MRQ)
522.18MCNY77.65M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1772xvs Biotechnology peers
Current Ratio (MRQ)
3.33xvs Biotechnology peers
Book Value per Share (MRQ)
23.75CNYUpdated Aug 21, 2026Total Assets
3.55BCNY528.57M · vs all stocks (USD)
Total Current Assets
1.69BCNYFY2025 · Dec 31, 2025Total Liabilities
625.71MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.86BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
158.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
467.58MCNYFY2025 · Dec 31, 2025Cash
450.80MCNYFY2025 · Dec 31, 2025Cash Equivalents
32.97MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
483.77MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.10BCNYFY2025 · Dec 31, 2025Accounts Receivable
39.41MCNYFY2025 · Dec 31, 2025Inventory
51.50MCNYFY2025 · Dec 31, 2025Accounts Payable
60.50MCNYFY2025 · Dec 31, 2025Short-term Debt
321.47MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.92MCNYFY2025 · Dec 31, 2025Long-term Debt
55.62MCNYFY2025 · Dec 31, 2025Common Stock (Book)
83.87MCNYFY2025 · Dec 31, 2025Retained Earnings
2.18BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.93BCNY435.52M · vs all stocks (USD)
52-Week Low
23.24CNYUpdated Aug 21, 202652-Week High
63.51CNYUpdated Aug 21, 202652-Week Change
-33.31%vs all stocks
Beta
0.7500xvs all stocks
50-Day MA
30.37CNYUpdated Aug 21, 2026200-Day MA
39.88CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.17MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.55MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.2600CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -0.10
Financial Health
Altman Z-Score 4.76: safe zoneNotable
Altman Z-Score: 4.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tilray Brands, Inc.
Tier 1ProductionApproval-Gated PipelineFlowAttention
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Shanghai Fudan Microelectronics Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline